DUSA Pharmaceuticals (DUSA) +37.7% premarket after agreeing to be acquired by India's Sun Pharma for $8/share, giving the deal a total cash value of ~$230M. The price represents a 38% premium to DUSA's closing price yesterday. Dermatology company DUSA develops and markets the Levulan photodynamic therapy platform for the face and scalp.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs